TY - JOUR
T1 - Management of multiple myeloma in older adults
T2 - Gaining ground with geriatric assessment
AU - Wildes, Tanya M.
AU - Campagnaro, Erica
N1 - Funding Information:
Dr. Wildes' research is supported by grant number 1K12CA167540 through the National Cancer Institute (NCI) at the National Institutes of Health (NIH) and grant number UL1 TR000448 through the Clinical and Translational Science Award (CTSA) program of the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NCI, NCATS or NIH.
Publisher Copyright:
© 2016 Elsevier Inc.
PY - 2017/1/1
Y1 - 2017/1/1
N2 - Multiple myeloma increases in incidence with age. With the aging of the population, the number of cases of multiple myeloma diagnosed in older adults each year will nearly double in the next 20 years. The novel therapeutic agents have significantly improved survival in older adults, but their outcomes remain poorer than in younger patients. Older adults may be more vulnerable to toxicity of therapy, resulting in decreased dose intensity and contributing to poorer outcomes. Data are beginning to emerge to aid in identifying which individuals are at greater risk for toxicity of therapy; comorbidities, functional limitations, and age over 80 years are among the factors associated with greater risk. Geriatric assessment holds promise in the care of older adults with multiple myeloma, both to allow modification of treatment to prevent toxicity, and to identify vulnerabilities that may require intervention. Emerging treatments with low toxicity and attention to individualizing therapy based on geriatric assessment may aid in further improving outcomes in older adults with multiple myeloma.
AB - Multiple myeloma increases in incidence with age. With the aging of the population, the number of cases of multiple myeloma diagnosed in older adults each year will nearly double in the next 20 years. The novel therapeutic agents have significantly improved survival in older adults, but their outcomes remain poorer than in younger patients. Older adults may be more vulnerable to toxicity of therapy, resulting in decreased dose intensity and contributing to poorer outcomes. Data are beginning to emerge to aid in identifying which individuals are at greater risk for toxicity of therapy; comorbidities, functional limitations, and age over 80 years are among the factors associated with greater risk. Geriatric assessment holds promise in the care of older adults with multiple myeloma, both to allow modification of treatment to prevent toxicity, and to identify vulnerabilities that may require intervention. Emerging treatments with low toxicity and attention to individualizing therapy based on geriatric assessment may aid in further improving outcomes in older adults with multiple myeloma.
KW - Aging
KW - Cancer
KW - Elderly
KW - Geriatric assessment
KW - Multiple myeloma
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=84964607366&partnerID=8YFLogxK
U2 - 10.1016/j.jgo.2016.04.001
DO - 10.1016/j.jgo.2016.04.001
M3 - Review article
C2 - 27118356
AN - SCOPUS:84964607366
SN - 1879-4068
VL - 8
SP - 1
EP - 7
JO - Journal of Geriatric Oncology
JF - Journal of Geriatric Oncology
IS - 1
ER -